Evidence map›Paper›PMID 37118546›Full record

ArticleNature aging2022

Suppression of de novo sphingolipid biosynthesis mitigates sarcopenia.

Edwin R Miranda, Katsuhiko Funai

Abstract read
In one paragraph

Article in Nature aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Potential Vitamin E Signaling Mediators in Skeletal Muscle.Antioxidants (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Edwin R MirandaDiabetes & Metabolism Research Center, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-2370-4118
Katsuhiko FunaiDiabetes & Metabolism Research Center, University of Utah, Salt Lake City, UT, USA. kfunai@health.utah.edu.ORCID 0000-0003-3802-4756

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1M
PE methylation in skeletal muscle energy efficiencyR01DK107397 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2017 to 2025
$3.8M
LOOH-induced muscle atrophy with ageR01AG074535 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Micah J Drummond, Katsuhiko Funai · 2022 to 2026
$3.0M
Lands cycle and skeletal muscle insulin actionR01DK127979 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2022 to 2025
$1.9M
PE In Modulation of Energy Flux Through OxphosR01GM144613 · NIGMS · UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2021 to 2024
$1.6M
NIA NIH HHS R01 AG074535NIDDK NIH HHS P30 DK020579NIDDK NIH HHS R01 DK107397NIDDK NIH HHS R01 DK127979NIGMS NIH HHS R01 GM144613
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

SarcopeniaHumansLipogenesisSphingolipidsSphingosineSphingolipidsSphingosine

Identifiers

PMID37118546
PMCPMC10148949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.